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Abstract
Objectives: Treatment of oral mucositis (OM) is challenging. In order to develop and test useful treatment approaches, the
development of reliable, reproducible and simpler methods than are currently available for assessment of OM is important.
A Patient-Reported Oral Mucositis Symptom (PROMS) scale was assessed in patients with head and neck cancer to
determine if the patient-reported OM experience, as determined by using the PROMS scale, correlate with OM assessed by
clinician-based scoring tools.
Materials and Methods: Fifty patients with head and neck cancer and undergoing radiotherapy consented to participate.
They were examined before cancer treatment and twice weekly during 6–7 weeks of therapy and once 4–6 weeks after
therapy. Signs of OM were evaluated using the 3 clinician-based scoring tools; NCI-CTCAE v.3, the OMAS criteria and the
Total VAS-OMAS. The participants’ OM experiences were recorded using PROMS-questionnaires consisting of 10 questions
on a visual analogue scale. Spearman rank correlation test were applied between the PROMS scale values and the clinician-
determined scores. Repeated measures mixed linear models were applied to appraise the strengths of correlation at the
different time points throughout the observation period.
Results: Thirty-three participants completed all stages of the study. The participant experience of OM using the PROMS
scale demonstrates good correlations (Spearman’s Rho 0.65–0.78, p,0.001) with the clinician-determined scores on the
group level over all time points and poor to good correlations (Spearman’s Rho -0.12–0.70, p,0.001) on the group level at
different time points during and after therapy. When mouth opening was problematic, i.e. during the 6th and 7th week after
commencing cancer treatment, the Spearman’s Rho varied between 0.19 and 0.70 (p,0.001).
Conclusion: Patient experience of OM, as reported by the PROMS scale may be a feasible substitute for clinical assessment
in situations where patients cannot endure oral examinations.
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Introduction
Numerous clinical studies have focused on mucosal toxicity
associated with cancer therapy, which is a common acute toxic
effect of radiotherapy in head and neck (H&N) cancer patients [1–
3]. Oral mucositis occurs in near all patients who receive H&N
radiotherapy to the oral cavity or oropharynx and is exacerbated
with concurrent chemotherapy [2,4]. Severe oral mucositis can be
very painful leading to decreased intake of food and drink and
clinically significant weight loss or dehydration (Fig. 1). Moreover,
the psychosocial consequences of debilitating oral mucositis can be
considerable since the additional morbidity and pain while
undergoing the cancer therapy may cause anxiety and depression
[5–8]. When severe oral mucositis develops, cancer treatment may
be modified or even halted which can limit the efficacy of
treatment, and this is estimated to occur in about 10–25% of all
patients [9–11], although interruption rates as high as 47% have
been reported [12]. Severe oral mucositis can lead to increased use
of healthcare resources, additional supportive care and even
hospitalization. The direct economic consequences of oral
mucositis induced by cancer therapies may be significant and
require allocation of considerable resources [13–15]. Unfortu-
nately, preventing and treating oral mucositis is difficult at best
[16,17]. It is critically important to develop and validate methods
that can be used to quantify the oral mucositis experienced by
patients in order to develop targeted interventions that efficiently
reduce this particular adverse effect of cancer treatment [18].
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Extensive resources have been used to find meaningful tools that
can be used for accurate assessment of the extent and severity of
oral mucositis and/or the burden of oral mucositis for individual
patients. Pain associated with oral mucositis is assumed to result
from visible ulcerations and from such a perspective it might make
sense to use ulceration surface area as a proxy for pain. However,
the relationship between size and/or extent of oral lesions and
pain is not straightforward and in this regard, other mechanisms of
pain experienced by patients with oral mucositis, including
neurobiological mechanisms cannot be ruled out [19]. There is
a newly emerging body of evidence suggesting that assessments of
oral mucositis should include a standardized instrument or a
combination of instruments that measure both physical and
functional factors, as well as patient-perception [20].
In addition to issues pertaining to assessment of oral mucositis
from a clinical perspective (e.g. when and/or if a patient must be
provided with less aggressive treatment due to the development of
oral mucositis), it has been difficult to assess the efficacy of any
particular management protocol for oral mucositis due to the lack
of a universally validated and clinically-relevant measurement tool
for oral mucositis. Even more importantly, when oral mucositis
severity is at its peak, the patient may be unable or unwilling to
open his or her mouth to permit a comprehensive clinical
assessment of the severity of oral mucositis [21]; a problem that
again would interfere with the ability to monitor the condition and
also assess the efficacy of various clinical interventions. Hence, in
this critical phase of cancer treatment, where a patient may
renounce further care, it is critically important to develop other
means for assessment of oral mucositis and for confirming the
efficaciousness of various treatment interventions for this condi-
tion.
Appraising subjective measures that demonstrate a close
correlation with intraoral clinical measures may be one strategy.
Two promising tools that rely on subjective measurement include
the Oral Mucositis Weekly Questionnaire – Head and Neck
patients (OMWQ-HN) scale, used in a cohort of head and neck
patients [22], and the Patient-Reported Oral Mucositis Symptom
(PROMS) scale in a cohort of patients undergoing bone marrow
transplantation [23]. The latter measurement tool should be
possible for use amongst patients receiving radiotherapy for head
and neck malignancy. Hence, a study was designed to evaluate the
feasibility of using the PROMS scale to (i) complement common
clinician-determined assessments of oral mucositis and (ii) possibly
substitute the common clinician-determined assessments of oral
mucositis in situations where patients with H&N cancer undergo-
ing treatment have difficulties in opening their mouths for a
complete clinical assessment. The hypothesis of this investigation is
that the relative magnitude of oral mucositis assessed by clinician-
based scoring tools correlates with patient- reported oral mucositis
experience as determined by using the PROMS scale.
Materials and Methods
A prospective single cohort study was designed to appraise the
merits of using the PROMS scale to measure how patients with
H&N cancer were affected by oral mucositis during their cancer
treatment. Approval was obtained from the Research Ethics
Boards of the University Health Network (#09-0231-CE) and
University of Toronto (# 24171), and written informed consent
was obtained from all study participants. The study was conducted
at the Princess Margaret Hospital/Ontario Cancer Institute
(PMH) in accordance with the ICH Harmonized Tripartite
Guidelines for Good Clinical Practice (http://www.pre.ethics.gc.
ca/eng/archives/tcps-eptc/Default/).
Participants
Potentially eligible participants were informed by the dental
department staff about the ongoing study. Eligible participants
were identified by being 18 years of age or greater and willing and
able to provide informed consent. Participation meant a commit-
ment to bi-weekly clinical examination during cancer treatment,
and at one postoperative examination. Patients with carcinoma of
the oral cavity, nasopharynx, oropharynx, salivary glands or the
maxillary sinus scheduled to receive radiotherapy for their cancer
with a minimum prescription radiation dose of 54Gy, with or
without concurrent chemotherapy were invited to participate in
the study. Patients also had a minimum Karnofsky score
performance status of 60% and no indications of active significant
acute or chronic diseases that might compromise the ability to
carry out intraoral assessment of mucositis. Potential participants
were advised that at the outset of the study there should be no
visible signs of ulcerations. Dental status was appraised as good at
the screening visit (no need for dental treatment), fair/poor (dental
treatment required before start of cancer treatment) or edentulous.
The study recruitment period ended when 50 participants had
been enrolled.
Measures
Participants were scheduled for appointments at baseline, twice
weekly over the course of their 6 to 7-week cancer treatment and
once more 4 to 6 weeks after completion of treatment. At each
appointment participants had an oral examination by a previous-
ly-calibrated investigator with the help of mouth mirrors and the
use of a high-power head-lamp as a light source. Participants
reported how oral mucositis which developed during the
radiotherapy period impacted on selected oral functions using
the PROMS-questionnaire. Analgesic use, need for hospital
admission, or the addition of nutritional support since the previous
examination was recorded based on self-reports provided by the
participants.
Clinical oral examination
Clinical signs of oral mucositis were recorded using three
different clinician-based scoring tools, two of which are probably
the most common tools used by clinicians worldwide, i.e., the
clinical component of the National Cancer Institute Common
Terminology Criteria for Adverse Events version 3 (NCI-CTCAE
Figure 1. Oral mucositis is a side-effect of radiation treatment
that leads to pain and limitations of mouth opening and
numerous oral functions.
doi:10.1371/journal.pone.0091733.g001
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v. 3) [24], and the clinical component of the Oral Mucositis
Assessment Scale (OMAS) [21]. The third tool has been developed
locally and is termed ‘‘TOTAL-VAS-OMAS’’ [23]. In the NCI-
CTCAE v. 3 the occurrence and severity of oral mucositis is
graded using an ordinal score ranging between 0 (none) and 4
(most) as observed at any site within the oral cavity. The OMAS
tool was used as described previously whereby a score of 0 (none)
and 3 (ulceration) or 2 (erythema) is assessed in nine specific intra-
oral locations. The ulceration and erythema scores were not
aggregated as in the original publication, but kept separate to
better elucidate possible correlations with the other clinician-based
scoring tools and the PROMS experience. Hence, the maximum
sum score of ulceration was 27 (9 sites x3) and of erythema 18
(962). The ‘‘TOTAL-VAS-OMAS’’ tool consists of two visual
analogue scales ranging between 0 to 100 mm for full mouth
assessments of erythema and ulceration respectively. The first
author (A.M.G.) undertook training and calibration in oral
mucositis assessment prior to initiation of the study until Kappa
= 1.0, by the use of a photographic set developed for such purposes
for the OMAS tool, kindly provided by Dr. Monique Stokman at
the University Medical Center Groningen, The Netherlands.
Additionally, a laminated booklet containing these images was
used during the study to maintain reliability. Most participants
made strong efforts to allow complete assessment of their oral
conditions, despite the presence, for example, of severe oral
mucositis. This suggested that the participants were motivated and
dedicated to the completion of this investigation. The oral
examinations were done independent of the patient-reported
measures.
Figure 2. PROMS scale questionnaire with the ten components each detailing two extremes of a functional characteristic within a
100 mm horizontal line or Visual Analogue Scale (VAS) (23).
doi:10.1371/journal.pone.0091733.g002
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Reporting of symptoms
The oral mucositis experience of the participants was assessed
by using the PROMS scale [23]. The PROMS scale consists of 10,
100-mm horizontal visual analogue scales addressing oral func-
tions affected by oral mucositis. Participants were asked to mark
on the 100 mm line what best represented their present intra-oral
condition (Fig. 2). During the baseline examination and prior to
their completion of the actual PROMS scale questionnaire,
participants were subjected to a few test-visual analogue scale
questions focused on simple everyday topics to familiarize them
with the concept of visual analogue scale assisted measurements.
The participants completed a PROMS questionnaire at each
clinical study appointment; baseline, twice per week during their
radiotherapy period and at the post-operative visit, prior to and
independently of the actual clinical oral examination.
Data management and statistical analyses
A power analysis was done a priori to establish a rank correlation
of rho = 0.90 between the PROMS scale and the NCI-CTCAE v.3
and/or OMAS scores and yielded a sample estimated size of 20
participants (Alpha level 0.05% and power of 80%, 2-tailed
correlations) (Sample power, SPSS Inc. Chicago, USA). Since
patients with H&N cancer may experience relatively high study
dropout rates [25], it was considered prudent to recruit 50
participants into the study.
All recordings were documented using de-identified case report
forms. The information from the case report forms was transferred
into a relational database (MS Access, Microsoft Inc. Redmont,
WA, USA). Repeated data entry verifications were made before
exporting the data matrices for statistical analysis. The measured
clinical and participant-reported variables were checked for
normal distribution to establish a potential need for log-
transformation corrections to obtain more precise p-values before
being subjected to Spearman rank correlation. Spearman rank
correlations were applied to characterize the relationships between
the PROMS scale and the NCI-CTCAE v.3 as well as OMAS &
TOTAL-VAS-OMAS scores using the statistical procedure
‘‘PROC CORR’’ in the SAS System Version 9.2 software (SAS
Table 1. Baseline Demographic and Clinical Characteristics of the participants who completed the full study (n = 33).
Characteristic Subcategory No. (%)
Sex Male 25 (76)
Female 8 (24)
Race Caucasian 27 (82)
Black 1 (3)
Asian 5 (15)
Age (years) Mean (Standard deviation, Range) 61 (10, 38–78)
Dental status Good 15 (45)
Fair/Poor 16 (49)
Edentulous 2 (6)
Smoking * Never 9 (29)
Present smoker 7 (22)
Ex-smoker 16 (50)
Alcohol* No 12 (38)
Yes 20 (62)
Primary tumour location Oral cavity/oropharynx 18 (55)
Salivary glands 6 (18)
Other 9 (27)









Chemotherapy No 18 (55)
Yes 15 (45)
Therapy length 4 weeks 1 (3)
6 weeks 7 (21)
7 weeks 25 (76)
*1 unknown.
doi:10.1371/journal.pone.0091733.t001
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Institute, Cary, NC, USA). To appraise the strengths of correlation
at the different time points throughout the observation period
robust repeated measures mixed linear models, ‘‘PROC
MIXED’’, were applied which account for the repeated nature
of the measurements. Finally, a Bonferroni correction was applied
to all statistical tests to account for multiple testing of the same
measures. Correlations showing a Spearman’s Rho of ,0.20 were
considered poor, 0.21–0.40 fair, 0.41–0.60 moderate, 0.61–0.80
good, and .0.80 very good [26].
Results
Fifty patients were recruited and followed throughout radiation
treatment between August 17, 2009 and July 19, 2010. During this
time 520 clinical examinations were undertaken, of which 500
were undertaken by the first author (A.M.G.). Thirty-three
participants completed the study, while 7 discontinued due to
exhaustion. Ten participants either did not start or had stopped
their cancer treatment (n = 7). Others were excluded because the
prescribed radiation dose was below 54 Gray (n = 3). Most
participants received radiation once daily for six (n = 7) or seven
weeks (n = 25), while one participant received radiation twice daily
for 4 weeks. Demographic information on participants who
completed the study can be seen in (Table 1).
Clinical signs and symptoms of oral mucositis
NCI-CTCAE scores for oral mucositis of ‘‘1’’ were observed as
early as the first week of cancer treatment, while scores of ‘‘3’’
started occurring towards the end of the second week. The
prevalence of the score ‘‘3’’ was close to 50% by the end of the
cancer treatment period (Fig. 3). This may be an underestimate as
intra-oral scoring was not possible in some participants due to their
inability or unwillingness to open their mouth for a complete
clinical assessment. At the post treatment examination about 50%
of the participants still demonstrated a NCI-CTCAE v.3 score of
‘‘2’’. The OMAS-Ulceration and -Erythema as well as the
TOTAL- VAS-Ulceration and -Erythema scores varied markedly
amongst participants at the different time-points. However, the
maximum scores were recorded consistently at the end of the 6–7
week fractionated radiotherapy period. At the post-treatment
examination the average scores were approximately a third of the
maximal scores reported during radiotherapy. The PROMS-
aggregated scores increased gradually during cancer treatment
period culminating with a visual analogue scale value of 60 by the
end of treatment. Hence, all measurements displayed similar
patterns of increasing oral mucositis scores with peaks at the end of
cancer treatment. Signs and symptoms of oral mucositis were still
present at the post-treatment examination carried out 4 to 6 weeks
after ending cancer treatment (Fig. 4).
Statistical correlations
The dataset used for statistical analyses was based on the 33
participants who completed the full study. The scorings of the 7
participants who discontinued the study did not appear to differ
from the remaining up to the point of their drop-out. The
normality of the data distribution of the measurement variables
was checked for skewness before applying the Spearman rank
correlation tests. Minimal skewness was observed, which enabled
correlation analyses without log-transformation. Very good
correlations (Spearman’s rho 0.86–0.96) were observed between
the different clinician-based scoring tools. Participant experience
of oral mucositis using the PROMS scale demonstrated good
Figure 3. NCI-CTCAE v.3 (Cumulative %) (No color = Score 0, Dark = Score 3) recorded over the cancer treatment period (7 weeks)
and at the 4–6 week post-therapy examination.
doi:10.1371/journal.pone.0091733.g003
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correlations on the group level with clinician-determined scores
over all the time points (Spearman’s Rho 0.65–0.78, p,0.001).
(Table 2). These correlations were performed over all time points
using a statistical model that accounted for the repeated nature of
the data assessment for calculation of p-values. PROMS scores for
participant experience of oral mucositis demonstrated poor to
good correlations on the group level at different time points with
the clinician-determined scores. (Spearman’s Rho -0.12–0.70,
p,0.001). The correlations between PROMS scales and the scores
obtained by measurement of clinical indices changed over time,
but specific trends could not be established. At the critical phase
where mouth opening was problematic, i.e., during the 6th and 7th
week after commencing cancer treatment, the Spearman’s Rho
varied between 0.19 and 0.70 (p, 0.001) (Fig. 5).
Discussion
Oncology patients that undergo cancer treatment needs
supporting care in time of extreme psychological duress [16–18].
Preventing and managing oral mucositis as a side-effect of the
therapy is an important contribution to increase the patient
endurance so he or she can tolerate and ultimately benefit from
the cancer therapy. The combination of clinician-observed signs of
oral mucositis and patient-reported experience of the symptoms of
oral mucositis appears to be the best approach to assess the
severity of oral mucositis, rather than relying exclusively on either
one or the other. The current study shows that the PROMS scale
can complement common clinician-determined assessments of oral
mucositis. Moreover, the PROMS can also substitute the common
clinician-determined assessments of oral mucositis in patients
where these can’t open their mouth or endure a comprehensive
clinical oral examination or simply can’t come to the treatment
centre. There are several occasions when comprehensive clinical
assessments of oral mucositis may be impossible, while data based
on PROMS assessment can almost always be obtained. In these
situations the PROMS score might be used to replace missing
clinical data on an individual patient level. If needed, the PROMS
questions can potentially be completed via telecommunications
equipment (e.g. Internet) to substitute a clinical oral mucositis
assessment during the cancer treatment.
It should be emphasized that the PROMS is not a measure of
quality of life and does not address psychological duress, but is
developed with an objective to elucidate the possible effectiveness
of any therapeutic interventions against oral mucositis. To
facilitate user-friendliness, only a limited number of questions
are asked, and these focus on simple everyday daily functions that
empirically are noted as side effects of radiotherapy. Including
more questions is not necessarily advantageous, since completing
the questionnaire will become more cumbersome for the patient.
Admittedly, some questions may be redundant, which will be the
focus of future studies. Moreover, including questions that would
rely on adequate cognitive function such as enquiry about
periodicity of burning sensations and incidence of bleeding would
be unreliable due to the patients’ extraordinary emotional
circumstances [6].
A general impression was that few participants had any
problems understanding the questions on the PROMS question-
naire relatively quickly. Moreover, completing the questionnaire
was perceived by most as quick and easy and not felt as
burdensome while they received their cancer treatments. If a
patient-reporting instrument, such as the PROMS scale is
implemented in routine care or as an outcome in a clinical trial
it should be stressed to the patients in an early stage of their cancer
treatment that the data generated from the PROMS may possibly
Figure 4. Clinical signs and patient symptoms recorded over
the observation period (7 weeks) and at the 4–6 week post-
therapy examination (‘‘P’’). From top to bottom: OMAS Scores for
Ulceration (Means +/2 SDs; maximum score = 27), OMAS Scores for
Erythema (Means +/2 SDs; maximum score = 18), TOTAL-VAS-OMAS
Score for Ulceration (Means +/2 SDs), TOTAL-VAS-OMAS Score for
Erythema (Means +/2 SDs) and PROMS scale value (Means +/2 SDs).
(All VAS scales: maximum value = 100).
doi:10.1371/journal.pone.0091733.g004
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Figure 5. Spearman rho correlation coefficients over the observation period (7 weeks) and at the 4–6 week post-therapy
examination between clinical signs of oral mucositis, as reported by different clinician-based scoring tools and the experience of
oral mucositis by the participants, as reported by the PROMS scale. PROMS scale value vs. scores for: NCI-CTCAE v.3 (a), OMAS-Ulceration (b),
OMAS Erythema (c), TOTAL-VAS-OMAS Ulceration (d) and TOTAL-VAS-OMAS Erythema (e).
doi:10.1371/journal.pone.0091733.g005
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become the only manner their intraoral oral mucositis status can
be assessed at later stages in the cancer treatment period.
The correlation between the data using the PROMS and the
clinician-based scoring tools were fairly similar over all the time
periods as well as during the critical 6th and 7th weeks period
during cancer treatment when the oral mucositis is at its worst.
The extent of ulceration was not a sufficient indicator of the
patient burdens experienced during the onset and development of
oral mucositis. Yet, should not the patient burden direct changes
in cancer treatment (ranging from reduction in the intensity of
treatment to total cessation of treatment) as opposed to what might
be less meaningful clinical assessments of lesion appearance and
size? As with management of other chronic conditions character-
ized by pain, including ‘chronic pain’ itself, it is the patient burden
that should ideally be used as the endpoint or outcome measure for
making decisions regarding further treatment of the condition, in
this case, oral mucositis. Thus, assessment of the extent of
ulceration as the most important and in some cases sole outcome
measure, while interesting and important from a mechanistic and
pathophysiological point of view is important, it would seem much
more critical to understand how a patient is functioning during
cancer treatment, and the patient’s relative extent of duress while
undergoing the treatment so that appropriate measures can be
taken. After all, a patient with ‘small’ areas of ulceration, but who
is demonstrating severe levels of suffering, may require interven-
tion, whereas a patient with larger ulcerations but minimal
symptoms may not. This is something that simply cannot be
measured by determining the size and/or extent of ulceration,
particularly since the pain associated with this condition is
considered complex and likely neuropathological in origin [19].
There was a large degree of heterogeneity in the participants of
the study, particularly in relation to the location of their
malignancy, tumour stage, sex and choice of radiotherapy
procedure. (Table 1). Since the study was designed to test for
the hypothesis that the patients’ self-reported experience of oral
mucositis correlated with other currently available measures of
oral mucositis, the impact of this heterogeneity was considered to
be of minor importance. There were no attempts to relate the oral
mucositis data to any specific demographic, clinical or other
extrinsic and intrinsic factors due to a high risk of spurious
associations.
The three clinician-based scoring tools have different charac-
teristics that need to be recognized. The clinical scoring of oral
mucositis with the use of the ordinal NCI-CTCAE v.3 tool is in
general straightforward, but borderline cases may be challenging
to differentiate using this tool. In particular, the distinction
between grades ‘2’ and ‘3’ can occasionally be challenging; a
characteristic that reinforces subjectivity in making assessments.
The challenge has apparently been recognized, since the NCI tools
have undergone several modifications over the years in order to
facilitate their use [24,27–29].
Using the clinical component of the OMAS scale is also
generally straightforward albeit more time consuming than using
the NCI-CTCAE v. 3 tool [24]. A calibration booklet such as the
one used in the current study facilitates scoring by visual
comparison with photographs. A characteristic of the OMAS tool
is that if severe oral mucositis is present in only one or two areas in
the oral cavity but minimal or absent elsewhere, the total score for
the severity of oral mucositis will be low, no matter how severely
ulcerated those one or two areas are. The authors of the original
paper outlined various ways of handling the sum-scores statisti-
cally, but ended up with more than one recommendation [21]. In
light of the experiences of patients suffering from oral mucositis, it
is uncertain whether having one area with severe erythema and/or
ulcerations is worse than having multiple areas that on their own
might be less severely involved. Moreover, it is not entirely clear
why one large ulcer should affect the patient more (or not) than
several small ulcerations.
The TOTAL-VAS-OMAS tool has so far only been tested by
the developers in one patient population [23], and there are no
published guideline documents regarding its use, challenges and
interpretations. In the lack of pictorial guides or descriptors there is
a possibility that observers, including the one in the current study
may create skewed data since relatively high scores can be given in
the early phases during cancer treatment before the really severe
cases of oral mucositis become observable. Regardless of which
clinician-based scoring tools is used, it is important that all sites of
the oral cavity are examined, which can be difficult or
uncomfortable at later stages of cancer treatment.
It is often tempting to interpret patient symptom data on inter-
individual rather than on intra-individual levels. Self-assessed
patients may enter a higher score than other patients depending
on several factors including, but not limited to, previous
experiences regarding illness or pain. Moreover, the number and
strength of narcotic and non-narcotic analgesics could also affect
self-reported experiences of mouth pain resulting from oral
mucositis. Conversely, some participants continued to report
significant mouth pain in spite of the use of high amounts of
analgesic medication [30].
Many consider correlations between patients’-recorded subjec-
tive measures and clinically recorded measures obtained by health
professionals as biased with high levels of variability. Attempts to
minimize bias in the current study were done by undertaking
calibration a priori, consistent use of a booklet/poster with clinical
photographs while appraising the participants and use of mainly
one single clinical examiner throughout the study. The great
majority of the clinical examinations were completed by one
investigator (A.M.G.), since one important factor for negative
Table 2. Spearman rho correlation coefficients over the full cancer treatment between clinical signs of oral mucositis, as reported
by different clinician-based scoring tools and the experience of oral mucositis by the participants, as reported by the PROMS scale
values.
OMAS-U OMAS-E TOTAL-VAS-OMAS-U TOTAL-VAS-OMAS- E PROMS
NCI- CTCAE v. 3 0.89 0.86 0.92 0.91 0.75
OMAS Ulcerate Area - 0.92 0.95 0.90 0.65
OMAS Erythema Area - - 0.91 0.92 0.69
TOTAL-VAS-OMAS Ulceration - - - 0.96 0.75
TOTAL-VAS-OMAS Erythema - - - - 0.78
doi:10.1371/journal.pone.0091733.t002
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experiences in cancer trial participation is involving many
physicians at check-up appointments [31]. Moreover, this assured
that measurements were done mainly by one calibrated investi-
gator which would tend to lead to less variability.Although there
appears to be a statistical correlation between clinical signs and
patient-reported symptoms on group level, multiple individuals
deviated from this pattern in this study. Consequently, there is a
possibility that subtle intra-individual improvements (or deterio-
rations) can be masked if the effectiveness of new therapeutic and
preventive interventions targeted towards oral mucositis is
determined on group level point estimates rather than on intra-
individual levels.
Conclusions
The current findings indicate good correlations between
assessment of the oral mucositis experience obtained from the
PROMS scale and currently available instruments used commonly
to assess oral mucositis in patients with head and neck cancer.
Hence, patient-based experiences of oral mucositis, as reported by
the PROMS scale, may be a useful tool to augment clinical
assessment of oral mucositis or as a substitute assessment in
situations where patients cannot endure oral examinations.
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